S
Tariq Arshad
Senior manager, WW commercial development, Pfizer
ROLE MODEL: Fred Hassan
HAS: "Infectious enthusiasm for my work"
Tariq Arshad has seen pharma's resource-strapped, generic-bedeviled future—and he's here to say that it can be handled. The experience came in his native Pakistan about 10 years ago. Arshad, after burning out as a pediatric oncologist, was working for Pharmacia & Upjohn. His challenge: maintain sales of the anxiety drug Xanax, even with hundreds of generic competitors.
Tariq Arshad
He arrived in New York a month after 9/11, survived the Pfizer–Pharmacia merger, and soon found himself working on doomed Exubera. Today, he handles both marketing and early commercial for Pfizer's Alzheimer's portfolio. "Anybody who aspires to a marketing leadership role has to spend time in the trenches, so to speak, working with R&D to optimize the commercial value of their assets," says Arshad. "Without doing that really, we won't be effective marketers once the product reaches launch stage."
These days, Arshad sees tactics at Pfizer he hasn't seen since Pakistan—a flattening structure, fewer marketing resources, and a willingness to learn how to compete with generics. It's an environment where he's already proved that he can thrive.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.